Fluzoparib

氟唑帕利

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameFluzoparib
Drug Alias NameFluazolepaliFluzopanibFuzuloparibFluzopalil艾瑞颐 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitors
TargetsPoly (ADP-Ribose) polymerase 1Poly (ADP-Ribose) Polymerase 2
Therapy Area/IndicationsSolid tumoursOvarian DiseasesRenal Insufficiency +[15] 
Global Approved IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms
Approved Indications in ChinaFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2020/12/11
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFujian Cancer HospitalTianjin Medical University Cancer Institute And HospitalJiangsu Hansoh Pharmaceutical Group Co Ltd +[6] 
Inactive CompaniesAtridia Pty Ltd
Active IndicationsSolid tumoursOvarian DiseasesRenal Insufficiency +[11] 
Inactive IndicationsProstatic Neoplasms, Castration-ResistantPancreatic NeoplasmsStomach Neoplasms +[4] 

Other Information

ATC CodeL01XE
Related LinksDrugBank